SUN-175 Factors Associated With Growth Velocity During GnRH Agonist Therapy In Girls With Central Precocious Puberty: A Retrospective Study

Abstract Disclosure: J. Kim: None. Background: Gonadotropin-releasing hormone agonist (GnRHa) treatment is the standard of care for central precocious puberty (CPP) to suppress premature pubertal progression and preserve final adult height. However, inter-individual variability in growth response during treatment remains, and the predictive factors of growth velocity (GV) after initiation of therapy are not fully established. This study aimed to identify clinical, hormonal, and auxological parameters associated with 6-month and 1-year growth velocity during GnRHa treatment in girls with CPP.Methods: We retrospectively reviewed medical records of 231 girls diagnosed with CPP who received GnRHa therapy. Growth velocity was calculated at 6 months (GV_6mo) and 12 months (GV_12mo), and also as the difference between the latter half-year and the first half-year (GV_12mo–6mo). Pearson correlation analyses were performed to examine associations between growth velocities and clinical (age, bone age, Tanner stage), anthropometric (height SDS, weight gain), and biochemical (LH, FSH, estradiol, IGF-1) variables, both at baseline and during follow-up.Results: At 6 months, growth velocity was positively correlated with baseline height SDS at 6 months (r = 0.198, P < 0.01), weight at 6 months (r = 0.174, P < 0.01), and weight gain over 6 months (r = 0.280, P < 0.01). Initial IGF-1 levels also showed a significant correlation with GV_6mo (r = 0.210, P < 0.01). At 12 months, significant positive correlations were observed with height SDS at 12 months (r = 0.351, P < 0.01), weight at 12 months (r = 0.212, P < 0.01), and weight gain over 12 months (r = 0.096, P < 0.05). However, a decline in growth velocity in the latter half-year (GV_12mo–6mo) was observed and was negatively correlated with bone age (BA_12mo: r = –0.092, P < 0.05), suggesting growth deceleration may reflect early responders plateauing over time. Notably, mid-parental height (MPH), initial peak LH, estradiol (E2), follow-up LH and E2 levels, and the type of GnRH agonist used were not significantly correlated with growth velocity at any time point.Conclusion: Early growth response during GnRHa treatment in girls with CPP is significantly influenced by baseline height status, weight gain, and IGF-1 levels. These parameters may assist clinicians in predicting individual growth trajectories and in tailoring follow-up intensity during treatment for CPP. Presentation: Sunday, July 13, 2025